Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access Protocol for Providing Tabelecleucel to Patients With Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies

NCT02822495 is registered in ClinicalTrials.gov with Atara Biotherapeutics as lead sponsor.

NCT NCT02822495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02822495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access Protocol for Providing Tabelecleucel to Patients With Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies
Lead sponsor
Atara Biotherapeutics
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ebv+ associated lymphoma, ebv+ associated post-transplant lymphoproliferative disease (ebv+ ptld), epstein-barr viremia, epstein-barr virus (ebv) infections, epstein-barr virus-associated lymphoproliferative disease (ebv+ lpd) with acquired immunodeficiency (aid), epstein-barr virus-associated lymphoproliferative disease (ebv+ lpd) with primary immunodeficiency (pid), leiomyosarcoma (lms), lymphoma, aids-related, lymphoproliferative disorders, nasopharyngeal carcinoma (npc), solid organ transplant complications, stem cell transplant complications